Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.

In 30 seconds

This randomized, split-face trial evaluated the efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for treating freckles in 84 Chinese patients. The investigational device showed noninferiority to the established system, with identical response rates of 97.6%. Participant satisfaction was significantly higher with the new device at 72.6%.

Key findings

• Response rates were identical at 97.6% for both devices, with a difference of 0.0%.
• Participant satisfaction was significantly higher with the investigational device at 72.6% compared to 58.3%.
• The cure rates were comparable at 13.1% for the investigational device and 9.5% for the control (p = .527).
• Treatment duration suggested an association with superior efficacy (OR = 2.07, p = .016).

Why it matters

The findings support the use of a novel laser technology for treating freckles, potentially improving patient satisfaction and access to effective dermatological treatments. Understanding the efficacy and safety of new devices is crucial for informed clinical decision-making.